Literature DB >> 26736010

Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.

Carlo Gambacorti-Passerini1, Lara Mussolin, Laurence Brugieres.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26736010     DOI： 10.1056/NEJMc1511045

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

Review 1.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

2.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

Authors:  Yael P Mossé; Stephan D Voss; Megan S Lim; Delphine Rolland; Charles G Minard; Elizabeth Fox; Peter Adamson; Keith Wilner; Susan M Blaney; Brenda J Weigel
Journal:  J Clin Oncol       Date:  2017-08-08       Impact factor: 44.544

3.  Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.

Authors:  Dylan Graetz; Kristine R Crews; Elizabeth M Azzato; Ravi K Singh; Susana Raimondi; John Mason; Marcus Valentine; Charles G Mullighan; Ashley Holland; Hiroto Inaba; Vasiliki Leventaki
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

4.  IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Authors:  Nina Prokoph; Nicola A Probst; Liam C Lee; Jack M Monahan; Jamie D Matthews; Huan-Chang Liang; Klaas Bahnsen; Ivonne A Montes-Mojarro; Elif Karaca-Atabay; Geeta G Sharma; Vikas Malik; Hugo Larose; Sorcha D Forde; Stephen P Ducray; Cosimo Lobello; Qi Wang; Shi-Lu Luan; Šárka Pospíšilová; Carlo Gambacorti-Passerini; G A Amos Burke; Shahid Pervez; Andishe Attarbaschi; Andrea Janíková; Hélène Pacquement; Judith Landman-Parker; Anne Lambilliotte; Gudrun Schleiermacher; Wolfram Klapper; Ralf Jauch; Wilhelm Woessmann; Gilles Vassal; Lukas Kenner; Olaf Merkel; Luca Mologni; Roberto Chiarle; Laurence Brugières; Birgit Geoerger; Isaia Barbieri; Suzanne D Turner
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

Review 5.  Targeted based therapy in nodal T-cell lymphomas.

Authors:  Dai Chihara; Milos Miljkovic; Swaminathan P Iyer; Francisco Vega
Journal:  Leukemia       Date:  2021-03-04       Impact factor: 11.528

6.  Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.

Authors:  Elif Karaca Atabay; Carmen Mecca; Qi Wang; Chiara Ambrogio; Ines Mota; Nina Prokoph; Giulia Mura; Cinzia Martinengo; Enrico Patrucco; Giulia Leonardi; Jessica Hossa; Achille Pich; Luca Mologni; Carlo Gambacorti-Passerini; Laurence Brugières; Birgit Geoerger; Suzanne D Turner; Claudia Voena; Taek-Chin Cheong; Roberto Chiarle
Journal:  Blood       Date:  2022-02-03       Impact factor: 22.113

7.  Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.

Authors:  Hugo Larose; Nina Prokoph; Jamie D Matthews; Michaela Schlederer; Sandra Högler; Ali F Alsulami; Stephen P Ducray; Edem Nuglozeh; Feroze M S Fazaludeen; Ahmed Elmouna; Monica Ceccon; Luca Mologni; Carlo Gambacorti-Passerini; Gerald Hoefler; Cosimo Lobello; Sarka Pospisilova; Andrea Janikova; Wilhelm Woessmann; Christine Damm-Welk; Martin Zimmermann; Alina Federova; Andrea Malone; Owen Smith; Mariusz Wasik; Giorgio Inghirami; Laurence Lamant; Tom L Blundell; Wolfram Klapper; Olaf Merkel; Amos G A Burke; Shahid Mian; Ibraheem Ashankyty; Lukas Kenner; Suzanne D Turner
Journal:  Haematologica       Date:  2021-06-01       Impact factor: 9.941

Review 8.  Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

Authors:  Coralie Hoareau-Aveilla; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

9.  Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Authors:  Carlo Gambacorti-Passerini; Sergey Orlov; Li Zhang; Fadi Braiteh; Huiqiang Huang; Taito Esaki; Keizo Horibe; Jin-Seok Ahn; Joseph T Beck; William Jeffrey Edenfield; Yuankai Shi; Matthew Taylor; Kenji Tamura; Brian A Van Tine; Shang-Ju Wu; Jolanda Paolini; Paulina Selaru; Tae Min Kim
Journal:  Am J Hematol       Date:  2018-02-08       Impact factor: 10.047

10.  Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma.

Authors:  Manuela Krumbholz; Wilhelm Woessmann; Jakob Zierk; David Seniuk; Paolo Ceppi; Martin Zimmermann; Vijay Kumar Singh; Markus Metzler; Christine Damm-Welk
Journal:  Oncotarget       Date:  2018-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.